Isofol Medical

The information in the press release is intended for investors.

Professor Frits Peters is professor emeritus at the Laboratory Medical Oncology, Amsterdam University Medical Center, professor at the Medical University of Gdansk, Poland, and honorary professor at Amity University in Noida, India.

The research of Frits Peters is focused on the development of new cancer treatments, from preclinical research to clinical phase I and II studies. He has been involved in several clinical studies of drug candidates that later gained market approvals for the treatment of cancer, such as gemcitabine, pemetrexed, S-1, TAS-102 and erlotinib. Notably, Frits Peters is recognized as a world leading expert on resistance and the pharmacology of chemotherapy and folate anticancer treatments.

“We are pleased and proud to have Frits Peters as an advisor to Isofol. Frits Peters is a leading folate expert and a leading opinion leader in the field, and his expertise is invaluable for the continued development of arfolitixorin. He has been involved with Isofol and the development of arfolitixorin for some time and has played a leading role in the design of our upcoming phase Ib/II clinical study,” says Petter Segelman Lindqvist, CEO of Isofol.

For more information, please contact
Isofol Medical AB (publ)
Petter Segelman Lindqvist, Chief Executive Officer 
E-mail: petter.s.lindqvist@isofolmedical.com
Phone: +46 (0) 739 60 12 56

The information was submitted for publication, through the agency of the contact person set out above, at 11:30 CET, on March 17, 2025.

About Isofol Medical AB (publ)
Isofol Medical AB (publ) is a research-based biotechnology company working to improve the prognosis for patients with severe forms of cancer. The company's drug candidate arfolitixorin aims to increase the effect of first-line standard treatment for several forms of solid tumors and is currently being studied in colorectal cancer, the world's third most common cancer, where the medical need for better treatments is urgent. A phase Ib/II study is now being conducted with new dosing regimens that are expected to optimize the effect of the drug candidate. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
www.isofolmedical.com